SCHEMBL1996607

SCHEMBL1996607

O=CNc1cncc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.53
ADRA2B P18089 1/20 0.53
ADRA2C P18825 1/20 0.53
ADRA1A P35348 1/20 0.53
HDAC6 Q9UBN7 1/20 0.43
PABPC1 P11940 1/20 0.42
PRKCZ Q05513 1/20 0.39
EGFR P00533 1/20 0.38
ERN1 O75460 4/20 0.38
ALDH1A1 P00352 2/20 0.38
TRPV1 Q8NER1 1/20 0.38
MALT1 Q9UDY8 1/20 0.37
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
SIRT3 Q9NTG7 1/20 0.36
HTT P42858 1/20 0.36
TSHR P16473 1/20 0.36
PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17577877 0.79 ROCK1 (0.55) HDAC6ALDH1A1TRPV1ROCK2ROCK1
SCHEMBL28163867 0.77 ROCK1 (0.54) HDAC6ALDH1A1TRPV1ROCK2ROCK1
SCHEMBL87813 0.76 PABPC1 (0.56) PABPC1ALDH1A1TSHRHSD17B10
SCHEMBL28218656 0.75 PABPC1 (0.55) PABPC1ALDH1A1TSHRHSD17B10
SCHEMBL2477411 0.75 ADRA2A (0.58) ADRA2AADRA2BADRA2CADRA1AHDAC6
SCHEMBL8352436 0.75 ADRA2A (0.62) ADRA2AADRA2BADRA2CADRA1AHDAC6
Hydrochloric Acid SCHEMBL28740125 0.75 PABPC1 (0.55) PABPC1ALDH1A1TSHRHSD17B10
SCHEMBL30743841 0.75 ADRA2A (0.62) ADRA2AADRA2BADRA2CADRA1AHDAC6
SCHEMBL1996604 0.74 ADRA2A (0.53) ADRA2AADRA2BADRA2CADRA1AHDAC6
SCHEMBL27730580 0.73 ALDH1A1 (0.49) HDAC6PABPC1ALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104334532-B Isoquinolin and naphthyridine derivative 霍夫曼-拉罗奇有限公司 2018-08-14 CN disclosed
CN-105263901-B α substituted glycyl amine derivatives 橘生药品工业株式会社 2017-06-23 CN disclosed
US-20120149703-A1 AZA-SUBSTITUTED SPIRO DERIVATIVES JITSUOKA MAKOTO (JP) 2012-06-14 US disclosed
US-8158791-B2 Aza-substituted spiro derivatives MSD K.K. (JP) 2012-04-17 US disclosed
US-7960394-B2 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
US-7960402-B2 Trans-5'-(2-fluoroethoxy)-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-isobenzofuran]-4-carboxamide hydrochloride; histamine H3 receptor antagonist or inverse agonist; metabolic disorders; circulatory diseases; nervous system diseases; psychological disorders; sleep disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
US-20090258871-A1 Aza-Substituted Spiro Derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-10-15 US disclosed
EP-1795527-B1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMA CO LTD (JP) 2009-04-22 EP disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US disclosed
EP-1953165-A1 AZA-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-08-06 EP disclosed
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative MSD K.K. (JP) 2008-07-17 US disclosed
EP-1795527-A1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-13 EP disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149703-A1 AZA-SUBSTITUTED SPIRO DERIVATIVES AZI2, NR3C2, DNMT3A ADRA2A 465/4885ADRA2B 551/4885ADRA2C 931/4885
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 ADRA2A 66/4885ADRA2B 278/4885ADRA2C 96/4885
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative HRH3, HRH4, HRH2 ADRA2A 305/4885ADRA2B 459/4885ADRA2C 605/4885
US-20090258871-A1 Aza-Substituted Spiro Derivatives AZI2, NR3C2, DNMT3A ADRA2A 465/4885ADRA2B 551/4885ADRA2C 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.